About Pharmaeconomica
From value demonstration to AI-enabled drug discovery.
Pharmaeconomica was incorporated in February 2023 to support life sciences and medtech organizations with health economics, value demonstration, market access, and evidence strategy. Shortly after, we expanded our ambition toward early drug discovery, with the goal of building an autonomous AI-enabled pipeline that can help identify, prioritize, and optimize promising therapeutic candidates.
Our story
We started with evidence and value. We are building toward autonomous discovery.
Pharmaeconomica began with a practical understanding of how life sciences products create value, generate evidence, and reach patients through reimbursement and market access decisions. That foundation shaped our broader vision: to use predictive modeling not only for access and evidence decisions, but also for earlier scientific decisions in drug discovery.
This is why Pharmaeconomica now combines two directions under one strategic logic: expert consulting in HEOR and market access, and AI-enabled discovery through PreditX®. Both are connected by the same principle: better models can reduce uncertainty and improve high-stakes life sciences decisions.
February 2023
Pharmaeconomica incorporated
Pharmaeconomica was incorporated as a Belgium-based life sciences company focused on health economics, value demonstration, market access, and evidence strategy.
2023
Health economics and value demonstration services
The company began by offering consulting services to life sciences and medtech organizations, supporting evidence generation, HEOR, value communication, and market access decision-making.
2023–2024
Expansion into early drug discovery
Shortly after its launch, Pharmaeconomica expanded its ambition beyond consulting. The company began developing the concept of an autonomous AI-enabled pipeline for early drug discovery.
2024–2025
Development of PreditX®
PreditX® emerged as Pharmaeconomica’s platform for target-based predictive screening, bioactivity prediction, ADMET and developability triage, and small-molecule candidate prioritization.
2025–2026
Toward generative molecular design
The next step is to extend the predictive core of PreditX® with generative AI capabilities for de novo molecular design, especially in data-scarce discovery environments.
Our mission
To reduce uncertainty across the life sciences value chain.
Our mission is to help life sciences organizations make better decisions from early discovery to evidence generation and market access. We do this by combining domain expertise, health economic thinking, computational science, and AI-enabled predictive modeling.
For discovery
We aim to help research teams prioritize targets, molecules, and development hypotheses before expensive experimental work begins.
For evidence
We help identify what evidence exists, what evidence is missing, and what information is needed to support credible value demonstration.
For access
We support strategy around health economics, reimbursement, payer expectations, value communication, and market access planning.
Our values
Principles that guide how we work.
Pharmaeconomica is built around scientific discipline, practical decision support, and responsible innovation.
Scientific rigor
We believe life sciences decisions must be grounded in credible evidence, transparent assumptions, and disciplined scientific reasoning.
Decision usefulness
Our work is designed to support real decisions, not just generate reports. We focus on what evidence means, what remains uncertain, and what should happen next.
Predictive thinking
Whether in health economics, market access, or early discovery, we use models to explore uncertainty, compare options, and anticipate future value.
Translational ambition
We aim to connect computational discovery, experimental validation, evidence generation, and market access into a coherent path from idea to impact.
Accessibility of innovation
We want advanced modeling and AI-enabled discovery capabilities to become accessible to smaller biotech companies, research groups, and institutions.
Responsible innovation
We see AI as a decision-support engine, not a shortcut. Human expertise, validation, and scientific accountability remain central to our approach.
Leadership
Multidisciplinary leadership across strategy, science, and AI.
Jorge Emilio Alfonso, MBA
Founder and CEO
Leads Pharmaeconomica’s strategy across health economics, market access, business development, innovation funding, and platform commercialization.
View LinkedIn →
Muhammad Usman Mirza, PhD
Co-founder and CSO
Leads scientific strategy in computational chemistry, molecular modeling, AI-driven drug discovery, and candidate prioritization.
View LinkedIn →
Kanzal Iman, PhD
Co-founder and Director AI/ML
Leads AI/ML, bioinformatics, computational structural biology, and platform intelligence for discovery workflows.
View LinkedIn →Contact
Want to discuss Pharmaeconomica, PreditX®, or a potential collaboration?
Contact us to discuss health economics, value demonstration, market access, evidence generation, predictive modeling, or AI-enabled drug discovery.
info@pharmaeconomica.com